Global Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Competitive Landscape Professional Research Report 2024

Global Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Competitive Landscape Professional Research Report 2024

Research Summary

Pharmacogenomics technology, also known as therapeutic diagnosis or companion diagnosis (CDx), involves the use of genetic information to personalize medical treatments, particularly in the field of drug prescription. It focuses on understanding how an individual＇s genetic makeup influences their response to medications. By analyzing genetic variations, such as single nucleotide polymorphisms (SNPs), pharmacogenomics aims to identify patients who are more likely to respond positively to a specific treatment, those who may experience adverse reactions, and individuals who may not respond effectively to certain drugs. Companion diagnostics play a crucial role in tailoring treatment plans, allowing healthcare providers to make more informed decisions about drug selection, dosage, and potential side effects based on a patient＇s genetic profile. This approach enhances the efficacy and safety of medical treatments, providing a more personalized and targeted approach to healthcare.

According to DIResearch's in-depth investigation and research, the global Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) market size will reach XX US$ Million in 2024, and is expected to reach XX US$ Million in 2030, with a CAGR of XX% (2025-2030). Among them, the China market has changed rapidly in the past few years. The market size in 2024 will be XX US$ Million, accounting for approximately XX% of the world. It is expected to reach XX US$ Million in 2030, and the global share will reach XX%.

The major global manufacturers of Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) include Qiagen, GE Healthcare, Agilent Technologies, F Hoffman La Roche, Foundation Medicine, Thermo Fisher Scientific, Leica Biosystems Nussloch, Pfizer etc. The global players competition landscape in this report is divided into three tiers. The first tiers is the global leading enterprise, which occupies a major market share, is in a leading position in the industry, has strong competitiveness and influence, and has a large revenue scale; the second tiers has a certain share and popularity in the market, actively follows the industry leaders in product, service or technological innovation, and has a medium revenue scale; the third tiers has a smaller share in the market, has a lower brand awareness, mainly focuses on the local market, and has a relatively small revenue scale.

This report studies the market size, price trends and future development prospects of Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx). Focus on analysing the market share, product portfolio, revenue and gross profit margin of global major manufacturers, as well as the market status and trends of different product types and applications in the global Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) market. The report data covers historical data from 2019 to 2023, base year in 2024 and forecast data from 2025 to 2030.

The regions and countries in the report include North America, Europe, China, APAC (excl. China), Latin America and Middle East and Africa, covering the Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.

The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.

Global Key Manufacturers of Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Include:

Qiagen

GE Healthcare

Agilent Technologies

F Hoffman La Roche

Foundation Medicine

Thermo Fisher Scientific

Leica Biosystems Nussloch

Pfizer

Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Product Segment Include:

PCR

In-situ Hybridization

Immunohistochemistry

Sequencing

Others

Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Product Application Include:

Oncology

Neurological Disorders

Cardiovascular Disease

Immunological Disorders

Others

Chapter Scope

Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trends

Chapter 2: Global Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Industry PESTEL Analysis

Chapter 3: Global Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Industry Porter’s Five Forces Analysis

Chapter 4: Global Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Major Regional Market Size and Forecast Analysis

Chapter 5: Global Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Market Size and Forecast by Type and Application Analysis

Chapter 6: North America Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 7: Europe Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 8: China Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 9: APAC (Excl. China) Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 10: Latin America Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 11: Middle East and Africa Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 12: Global Pharmacogenomics Technology/Therapeutic Diagnosis/Companion Diagnosis (CDx) Competitive Analysis of Key Manufacturers (Revenue, Market Share, Regional Distribution and Industry Concentration)

Chapter 13: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)

Chapter 14: Industrial Chain Analysis, Include Raw Material Suppliers, Distributors and Customers

Chapter 15: Research Findings and Conclusion

Chapter 16: Methodology and Data Sources